Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Mental Health Watchdog Launches Psychiatric Drug Side Effects Database—Search All Drug Regulatory Agency Warnings, Studies & Adverse Reactions Reports
  • USA - English


News provided by

Citizens Commission on Human Rights International

Aug 14, 2013, 11:00 ET

Share this article

Share toX

Share this article

Share toX


According to the FDA's MedWatch system, between 2004 and 2012, there were more than four hundred thousand adverse reactions from psychiatric drugs reported to the federal drug agency, including drug induced attempted and completed suicides and homicides.

Post this

Los Angeles, California (PRWEB) August 14, 2013 -- With one in five Americans currently taking prescribed psychiatric drugs (according to Medco Health Solutions), the mental health watchdog, Citizens Commission on Human Rights (CCHR), is concerned the public are not being accurately informed of the documented risks. Taking its commitment to inform and protect the public on mental health issues to a new level, CCHR has launched a comprehensive redesign of its website (http://www.cchrint.org) and enhanced drug database which features 211 psychiatric drug regulatory agency warnings, 223 studies, and over 400,000 adverse reactions reported to the US FDA by doctors, pharmacists, health care providers and consumers.

Wholly aware that trying to sift through the massive amount of data available on the web can be daunting to even the most seasoned researcher, CCHR painstakingly created the definitive guide to documented psychiatric drug side effects, taking the official FDA adverse reaction reports (MedWatch data), international drug regulatory agency warnings and studies, then summarized the often complex information into an easy, user-friendly format for consumers, researchers and policy makers.

For example, the FDA itself does not provide a way for the public to easily utilize the adverse reaction reports contained on their website, and while the data is available for downloading, it requires a programmer to decrypt the complex coding system, comprised of seven text files—over 94,000 pages per year (see side bar image for example of text files.) More than 2,000 hours were spent compiling the data into a user friendly format, which is now available for the general public. Now anyone can easily search side effects reported to the FDA (by doctors, pharmacists, health care providers and consumers) as well as international drug regulatory agency warnings and studies issued on antidepressants, antipsychotics and psycho-stimulants to name a few.

According to the FDA's MedWatch data, between 2004 and 2012, there were more than four hundred thousand adverse reactions from psychiatric drugs reported to the federal drug agency, including drug induced attempted and completed suicides and homicides. While the FDA itself estimates that less than 1% of all serious adverse events are reported directly to it, CCHR states the importance of the Medwatch data is that it represents some of the only post-market surveillance data on psychiatric drugs available. The fact is, the FDA approves psychiatric drugs for public consumption based on short term clinical drug trials (frequently only 6-8 weeks) and does not require drug makers to study the drug’s long term effects once they are out in the consumer market and out of the controlled protocols of drug makers.

In addition to the interactive drug database, CCHR also created web pages summarizing all documented risks of the main classes of psychiatric drugs, such as the following:

Antidepressant drug risks - 99 drug regulatory agency warnings, 119 studies, and 136,239 adverse reactions reported to the FDA. These include:

• self-harm
• anxiety
• withdrawal symptoms
• death
• mania or psychosis
• hallucinations or delusional thinking
• depression
• sexual dysfunction
• homicidal ideation
• diabetes

Antipsychotic drug risks - 55 drug regulatory warnings, 77 studies, and 118,624 adverse reactions reported to the FDA, including:

• death/sudden death
• heart problems
• withdrawal symptoms
• convulsions, seizures or tremors
• diabetes
• birth defects
• agitation
• mania and psychosis
• sexual dysfunction

ADHD drug risks - 31 drug regulatory warnings, 20 studies, and 17,702 adverse reactions reported to the FDA, including:

• heart problems
• mania/psychosis
• death
• hallucinations
• depression
• violence, hostility or aggression
• seizures
• suicide risk/attempts
• anxiety

Anti-anxiety drug risks - 17 drug regulatory warnings, 18 studies, and 35,230 adverse reactions reported to the FDA. These include:

• death and sudden death
• violence
• homicidal ideation
• suicide risk/attempts
• birth defects
• addiction

There are also summarized pages for specific top-selling, brand-name drugs such as Prozac, Paxil, Zoloft, Celexa, Ripserdal, Seroquel, Ativan, Ritalin, Adderall, Concerta, Provigil, Klonopin, Ambien, Xanax, and many more.

Too often, important scientific studies are lost on the public due to the confusing and complex nature of such reporting. In an effort to make this information available on a more basic level, the interactive psychiatric drug database allows users to customize their searches by class of drug, brand name of drug, age range and/or a particular side effect. The drug database was created by CCHR as a free public service.

View the new website here and the new Psychiatric Drug Side Effects Database here.

Media Department, Citizens Commission on Human Rights International, http://www.cchrint.org, +1 (323) 467-4242, [email protected]

Modal title

Example of the code from the FDA's adverse reaction reports, which comprises over 94,000 pages of text per year.
Example of the code from the FDA's adverse reaction reports, which comprises over 94,000 pages of text per year.
Example of the code from the FDA's adverse reaction reports, which comprises over 94,000 pages of text per year.

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.